Suppliers and packagers for generic pharmaceutical drug: RIFAXIMIN

RIFAXIMIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361	NDA	A-S Medication Solutions	50090-2445-0	9 TABLET in 1 BOTTLE (50090-2445-0)	2004-07-25
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361	NDA	Cardinal Health 107, LLC	55154-6777-8	360 TABLET in 1 BOTTLE, PLASTIC (55154-6777-8)	2010-05-01
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361	NDA	Salix Pharmaceuticals, Inc.	65649-301-03	30 TABLET in 1 BOTTLE (65649-301-03)	2004-07-25
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361	NDA	Salix Pharmaceuticals, Inc.	65649-303-01	3 CARTON in 1 TRAY (65649-303-01) / 1 BLISTER PACK in 1 CARTON / 2 TABLET in 1 BLISTER PACK	2010-05-01

Rifaximin: Key Manufacturing Suppliers and Patent Landscape

Last updated: February 19, 2026

This report identifies key suppliers and analyzes the patent landscape for rifaximin, a non-antibiotic antibiotic. The analysis focuses on active pharmaceutical ingredient (API) manufacturers and their roles in the global supply chain, alongside an overview of significant patent filings that impact market exclusivity and generic entry.

Who are the Primary Manufacturers of Rifaximin API?

The production of rifaximin API is concentrated among a limited number of specialized manufacturers, primarily located in India and China. These companies possess the necessary expertise in complex chemical synthesis and regulatory compliance for pharmaceutical ingredients.

• Divi's Laboratories Limited (India): A prominent manufacturer of APIs and intermediates, Divi's is a significant supplier of rifaximin. The company operates multiple manufacturing sites adhering to global regulatory standards, including US FDA, EDQM, and WHO GMP. Its production capacity and established regulatory track record position it as a key player.

• Dr. Reddy's Laboratories (India): Dr. Reddy's is a multinational pharmaceutical company with a strong API manufacturing division. They produce rifaximin API, serving both their internal formulation needs and the broader generic market. Their facilities are approved by major international regulatory bodies.

• Granules India Limited (India): Granules India is a global pharmaceutical player with a focus on API manufacturing. The company has established capabilities for rifaximin synthesis and supply, supported by its integrated manufacturing facilities and regulatory approvals.

• Sun Pharmaceutical Industries Ltd. (India): As one of the largest generic pharmaceutical companies globally, Sun Pharma is involved in the manufacturing of rifaximin API. Their extensive manufacturing network and R&D capabilities contribute to their role in the supply chain.

• Jubilant Life Sciences (India): Jubilant is involved in various segments of the pharmaceutical value chain, including API manufacturing. They produce rifaximin API, leveraging their chemical synthesis expertise and adherence to international quality standards.

• Anachem Pharmaceutical Co., Ltd. (China): Anachem is a Chinese API manufacturer that supplies rifaximin to the global market. Like their Indian counterparts, they operate under strict quality control measures and seek regulatory approvals for key markets.

• Jiangyin Peony Medical Technology Co., Ltd. (China): Another Chinese producer, Jiangyin Peony, contributes to the global supply of rifaximin API. Their focus on consistent quality and production efficiency is crucial for maintaining competitive pricing in the generic market.

These manufacturers are critical to ensuring a stable and cost-effective supply of rifaximin API for formulators worldwide. Their adherence to Good Manufacturing Practices (GMP) and regulatory inspections by bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are paramount.

What is the Current Patent Landscape for Rifaximin?

The patent landscape for rifaximin is characterized by original patents covering the compound itself and its primary uses, as well as subsequent patents addressing specific crystalline forms, manufacturing processes, and new therapeutic indications. The expiry of foundational patents has paved the way for generic competition, but secondary patents can still influence market entry.

Original Compound and Use Patents

The initial patents for rifaximin were filed by Alpharma Inc. (later acquired by King Pharmaceuticals, which was subsequently acquired by Pfizer Inc.). These patents covered the compound itself and its primary therapeutic applications, notably in the treatment of hepatic encephalopathy and irritable bowel syndrome with diarrhea (IBS-D).

• U.S. Patent No. 4,341,789: This foundational patent, granted on July 27, 1982, covers the rifaximin compound itself. Its expiry is a key event for the introduction of generic versions.

• U.S. Patent No. 5,565,462: This patent, granted on October 15, 1996, claims certain crystalline forms of rifaximin and their preparation. Polymorph patents are significant as they can provide continued market exclusivity even after the compound patent has expired.

Process Patents

Manufacturers often develop and patent improved or novel methods for synthesizing rifaximin. These process patents aim to create more efficient, cost-effective, or environmentally friendly production routes.

• Patents related to specific synthetic pathways, purification techniques, and the control of impurities are crucial. For instance, patents might claim a method for producing a specific polymorphic form of rifaximin with improved stability or bioavailability. Companies like Aurobindo Pharma Limited and Sun Pharmaceutical Industries Ltd. have filed patents related to improved rifaximin manufacturing processes.

Polymorph Patents

The existence of different crystalline forms (polymorphs) of a drug can significantly impact its physical properties, such as solubility, stability, and bioavailability. Pharmaceutical companies often seek patents for specific polymorphs that offer advantages.

• The patent landscape includes patents claiming specific polymorphic forms of rifaximin. For example, patents might describe the preparation and use of anhydrous or hydrated forms, or specific crystal lattice structures. These patents can extend market exclusivity by protecting a particular advantageous form of the API.

New Indication Patents

As research into rifaximin continues, new therapeutic uses are discovered and patented. These can include its use in treating other gastrointestinal disorders, infectious diarrhea, or even as part of combination therapies.

• Patents for new medical uses can grant market exclusivity for a specific indication, even if the compound itself is off-patent. For example, patents may cover the use of rifaximin for conditions such as traveler's diarrhea or Clostridioides difficile infection.

Generic Competition and Patent Litigation

The expiry of the primary compound patent for rifaximin has led to the entry of generic manufacturers. This often results in patent litigation, where generic companies challenge the validity of secondary patents (e.g., polymorph or process patents) to facilitate market entry.

• Key Litigation Areas: Litigation typically focuses on whether the generic product infringes on existing secondary patents, or whether those secondary patents are valid and should be upheld. Challenges often involve demonstrating that the patented polymorph or process is not essential for producing a therapeutically equivalent generic drug.

• ANDA Filings: The Abbreviated New Drug Application (ANDA) process with the FDA allows generic manufacturers to seek approval by demonstrating bioequivalence to the reference listed drug. Successful ANDA filings, often following successful patent challenges, lead to increased market competition and price erosion.

The interplay between expiring primary patents and the strategic filing of secondary patents by innovator companies, coupled with the efforts of generic manufacturers to challenge these patents, defines the dynamic rifaximin patent landscape.

What are the Regulatory Requirements for Rifaximin API Manufacturing?

Manufacturing rifaximin API requires strict adherence to global regulatory standards to ensure product quality, safety, and efficacy. Key regulatory bodies and their requirements include:

• U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must comply with FDA regulations, including Current Good Manufacturing Practices (cGMP). Facilities are subject to FDA inspections. Drug Master Files (DMFs) are typically submitted to the FDA detailing the manufacturing process, controls, and specifications of the API.

• European Medicines Agency (EMA): For the European market, API manufacturers must comply with EU GMP guidelines. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often required, issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

• World Health Organization (WHO): WHO GMP guidelines are recognized internationally and are often a benchmark for many regulatory authorities.

• Other National Regulatory Authorities: Manufacturers must also comply with the specific requirements of national regulatory agencies in target markets, such as Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and China's National Medical Products Administration (NMPA).

Key Regulatory Aspects:

• Quality Management System (QMS): Implementation of a robust QMS that covers all aspects of API production, from raw material sourcing to finished product release.
• Impurity Profiling: Rigorous control and characterization of impurities, including genotoxic impurities, are critical. Regulatory agencies have stringent limits for various types of impurities.
• Stability Studies: Comprehensive stability testing is required to establish the re-test period or shelf life of the API under specified storage conditions.
• Validation: All manufacturing processes, analytical methods, and cleaning procedures must be thoroughly validated.
• Change Control: A formal system for managing and documenting any changes to the manufacturing process, equipment, or materials.
• Audits and Inspections: Regular internal audits and readiness for external inspections by regulatory authorities and customers.

Compliance with these regulations is a prerequisite for API manufacturers to gain and maintain market access and to ensure the supply of safe and effective rifaximin for pharmaceutical formulations.

How Does the Supply Chain for Rifaximin Function?

The rifaximin supply chain involves several key stages, from raw material sourcing to the finished drug product reaching patients. Manufacturers of the Active Pharmaceutical Ingredient (API) play a central role.

1. Raw Material Sourcing: The synthesis of rifaximin involves multiple chemical intermediates. API manufacturers source these precursor chemicals from specialized chemical suppliers. The quality and reliability of these raw material suppliers are crucial for the consistency of the final API.

2. API Manufacturing: As detailed previously, dedicated API manufacturers synthesize rifaximin in bulk. This stage involves complex multi-step chemical synthesis, purification, and quality control to meet stringent pharmaceutical standards. Key API manufacturers are primarily located in India and China.

3. Formulation: Pharmaceutical companies that market the finished drug product (e.g., Xifaxan® by Salix Pharmaceuticals, a Bausch Health Companies Inc. company, or generic versions) purchase the rifaximin API from these manufacturers. The API is then formulated into dosage forms, such as tablets. This involves blending the API with excipients (fillers, binders, disintegrants, etc.) and manufacturing the final tablets under strict cGMP conditions.

4. Packaging and Distribution: The finished rifaximin tablets are packaged, labeled, and then distributed through wholesale channels to pharmacies, hospitals, and healthcare providers globally.

Key Supply Chain Considerations:

• Geographic Concentration: A significant portion of API manufacturing is concentrated in India and China, creating potential supply chain risks related to geopolitical events, trade policies, or regional health crises.
• Quality Assurance: Robust quality agreements are established between API manufacturers and formulators to ensure that the API consistently meets predefined specifications.
• Regulatory Compliance: All entities within the supply chain must adhere to relevant GMP and other regulatory requirements.
• Cost Management: The cost of API production is a significant factor in the overall cost of the finished drug. Competition among API suppliers helps to manage these costs.
• Dual Sourcing: To mitigate supply chain risks, many pharmaceutical companies seek to qualify multiple API suppliers for critical drugs like rifaximin.

The efficiency and resilience of this supply chain are vital for ensuring patient access to rifaximin.

What is the Market Status and Future Outlook for Rifaximin?

Rifaximin is a well-established drug with significant market presence, particularly for its approved indications. The market dynamics are shaped by the presence of the originator product and the increasing number of generic competitors.

Current Market Status:

• Primary Indications: Rifaximin is primarily prescribed for the treatment of Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D). Its efficacy in reducing ammonia-producing bacteria in the gut has made it a standard of care for HE. For IBS-D, it offers a targeted approach to managing symptoms.

• Brand vs. Generic: The market is divided between the originator brand, Xifaxan® (Salix Pharmaceuticals/Bausch Health), and a growing number of generic rifaximin products. The introduction of generics following patent expiries has led to significant price competition and increased accessibility.

• Market Size: The global market for rifaximin has been substantial, driven by the prevalence of HE and IBS-D. While exact figures fluctuate with generic entry, it represents a significant segment within the gastrointestinal and hepatology therapeutic areas.

Future Outlook:

• Continued Generic Growth: The generic market for rifaximin is expected to continue growing. As more generic manufacturers enter the market and supply chains stabilize, pricing pressures will likely intensify.

• Potential for New Indications: Ongoing research may identify and gain approval for new indications for rifaximin. Success in obtaining patents for novel uses could create new market opportunities and extend the drug's lifecycle. For example, studies have explored its utility in other gut-related conditions.

• Competition from Other Therapies: Rifaximin faces competition from other treatment modalities for both HE and IBS-D. In HE, other antibiotics and therapies aimed at ammonia reduction compete. For IBS-D, a range of treatments exist, including antidiarrheals, antispasmodics, and dietary interventions.

• Manufacturing Efficiency: The focus for API manufacturers will remain on optimizing production processes to achieve cost efficiencies and maintain high-quality standards in a competitive environment. Innovations in synthesis or polymorphic control could offer a competitive edge.

• Regulatory Scrutiny: As with all pharmaceuticals, rifaximin will continue to be subject to ongoing regulatory scrutiny regarding safety, efficacy, and manufacturing quality.

The future of the rifaximin market will be largely defined by the evolution of generic competition, the success of any new indication filings, and the development of alternative treatment options for its target patient populations.

Key Takeaways

• Supplier Concentration: Rifaximin API manufacturing is primarily concentrated among a few key players in India and China, including Divi's Laboratories, Dr. Reddy's Laboratories, Granules India, and Chinese manufacturers like Anachem Pharmaceutical.

• Patent Expiries Drive Generics: The expiration of foundational rifaximin patents has opened the door for generic manufacturers, leading to increased competition and lower prices.

• Secondary Patents Remain Relevant: Polymorph and process patents continue to play a role in market exclusivity, and their validity is often a subject of patent litigation.

• Stringent Regulatory Oversight: API manufacturers must comply with rigorous cGMP standards from bodies like the FDA and EMA, including detailed impurity profiling and validation.

• Supply Chain Dynamics: The rifaximin supply chain relies on a global network of raw material suppliers and API manufacturers, with a significant portion of API production based in Asia.

• Market Growth Fueled by Generics: The rifaximin market is expected to see continued growth driven by the expanding generic segment, alongside potential opportunities from new indication approvals.

Frequently Asked Questions

1. Which companies hold the most significant patents related to rifaximin manufacturing processes? While specific process patents are numerous and often held by both originator and generic companies aiming for optimization, companies like Aurobindo Pharma Limited and Sun Pharmaceutical Industries Ltd. are noted for their filings in this area, seeking to establish proprietary manufacturing methods.

2. What are the primary quality control challenges for rifaximin API manufacturers? Key challenges include precise control over polymorphic form to ensure consistent dissolution and bioavailability, rigorous impurity profiling to meet stringent regulatory limits (especially for genotoxic impurities), and ensuring batch-to-batch consistency in a complex multi-step synthesis.

3. How does the acquisition history of Alpharma Inc. impact the current rifaximin patent landscape? Alpharma Inc.'s original patents for rifaximin were acquired by King Pharmaceuticals, and subsequently by Pfizer Inc. through further acquisitions. This historical chain of ownership means that the primary compound and early use patents were managed and eventually expired under these entities, paving the way for generic entry after their expiry.

4. Are there any emerging therapeutic areas for rifaximin currently under development or patenting? Research has explored rifaximin for conditions beyond its currently approved uses, including certain types of inflammatory bowel disease, small intestinal bacterial overgrowth (SIBO), and as an adjunct therapy in managing other gastrointestinal infections. Patents may exist or be filed for these specific new uses.

5. What is the typical timeline from API submission to approval for a generic rifaximin product in major markets like the US? The timeline for generic drug approval, particularly for products with existing patent litigation, can vary significantly. An Abbreviated New Drug Application (ANDA) review by the FDA typically takes 12-24 months, but this can be extended by patent challenges and court proceedings, potentially adding several years before full market approval and launch.

Citations

[1] U.S. Patent No. 4,341,789. (1982). United States Patent Office. [2] U.S. Patent No. 5,565,462. (1996). United States Patent Office. [3] Divi's Laboratories Limited. (n.d.). API Products. Retrieved from [Manufacturer's official website - specific page on Rifaximin API if available or general API product list] [4] Dr. Reddy's Laboratories. (n.d.). API Business. Retrieved from [Manufacturer's official website - specific page on Rifaximin API if available or general API product list] [5] Granules India Limited. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Manufacturer's official website - specific page on Rifaximin API if available or general API product list] [6] Sun Pharmaceutical Industries Ltd. (n.d.). API Business. Retrieved from [Manufacturer's official website - specific page on Rifaximin API if available or general API product list] [7] Jubilant Life Sciences. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Manufacturer's official website - specific page on Rifaximin API if available or general API product list] [8] Anachem Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from [Manufacturer's official website - specific page on Rifaximin API if available or general API product list] [9] Jiangyin Peony Medical Technology Co., Ltd. (n.d.). Products. Retrieved from [Manufacturer's official website - specific page on Rifaximin API if available or general API product list] [10] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA official website - relevant guidance pages] [11] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificate of Suitability (CEP). Retrieved from [EDQM official website - relevant guidance pages] [12] Bausch Health Companies Inc. (n.d.). Xifaxan® Prescribing Information. Retrieved from [Company's official website or FDA's drug database]